165 related articles for article (PubMed ID: 14747843)
21. Where will new drugs come from?
Lancet; 2011 Jan; 377(9760):97. PubMed ID: 21215869
[No Abstract] [Full Text] [Related]
22. Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework.
Cook D; Brown D; Alexander R; March R; Morgan P; Satterthwaite G; Pangalos MN
Nat Rev Drug Discov; 2014 Jun; 13(6):419-31. PubMed ID: 24833294
[TBL] [Abstract][Full Text] [Related]
23. Rho Chi lecture. Pharmaceutical sciences in the next millennium.
Triggle DJ
Ann Pharmacother; 1999 Feb; 33(2):241-6. PubMed ID: 10084422
[TBL] [Abstract][Full Text] [Related]
24. [Dismantling of "Big Pharma" gives new impetus to the pharmaceutical sector. Dynamic life science clusters can increase Swedish competitiveness].
Hedner T; Gatenbeck L
Lakartidningen; 2012 Jun 27-Jul 17; 109(26-28):1280-1. PubMed ID: 22852257
[No Abstract] [Full Text] [Related]
25. Prescription for an ailing pharmaceutical industry.
Demain AL
Nat Biotechnol; 2002 Apr; 20(4):331. PubMed ID: 11923826
[No Abstract] [Full Text] [Related]
26. Antibacterial drug discovery: is small pharma the solution?
Boggs AF; Miller GH
Clin Microbiol Infect; 2004 Nov; 10 Suppl 4():32-6. PubMed ID: 15522038
[TBL] [Abstract][Full Text] [Related]
27. New drug development in the United States from 1963 to 1999.
Dimasi JA
Clin Pharmacol Ther; 2001 May; 69(5):286-96. PubMed ID: 11371996
[No Abstract] [Full Text] [Related]
28. Bigger companies for better drugs?
Lancet; 1995 Sep; 346(8975):585. PubMed ID: 7650996
[No Abstract] [Full Text] [Related]
29. Notable deals in the pharmaceutical industry in the fourth quarter of 2016.
D'Souza P
Drugs Today (Barc); 2017 Jan; 53(1):75-82. PubMed ID: 28387386
[TBL] [Abstract][Full Text] [Related]
30. Complementary new approaches enable repositioning of failed drug candidates.
Tartaglia LA
Expert Opin Investig Drugs; 2006 Nov; 15(11):1295-8. PubMed ID: 17040191
[TBL] [Abstract][Full Text] [Related]
31. [Early achievements of the Danish pharmaceutical industry-7].
Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
Theriaca; 2014; (42):31-62. PubMed ID: 25816561
[TBL] [Abstract][Full Text] [Related]
32. A decade of fragment-based drug design: strategic advances and lessons learned.
Hajduk PJ; Greer J
Nat Rev Drug Discov; 2007 Mar; 6(3):211-9. PubMed ID: 17290284
[TBL] [Abstract][Full Text] [Related]
33. Rediscovering plant-based drugs.
Littleton J; Falcone D; Davies HM
Nat Biotechnol; 2003 Aug; 21(8):843-4. PubMed ID: 12894188
[No Abstract] [Full Text] [Related]
34. Merger with AstraZeneca will create a scientific "powerhouse," says Pfizer.
O'Dowd A
BMJ; 2014 May; 348():g3341. PubMed ID: 25134152
[No Abstract] [Full Text] [Related]
35. How should we support pharmaceutical innovation?
Grootendorst P
Expert Rev Pharmacoecon Outcomes Res; 2009 Aug; 9(4):313-20. PubMed ID: 19670991
[TBL] [Abstract][Full Text] [Related]
36. Combating the cons of consolidation.
Nat Rev Drug Discov; 2009 Mar; 8(3):177. PubMed ID: 19263592
[No Abstract] [Full Text] [Related]
37. [An analysis of the pharmaceuticals market in Vietnam].
Simonet D
Sante; 2001; 11(3):155-60. PubMed ID: 11641078
[TBL] [Abstract][Full Text] [Related]
38. An overview of the pharmaceutical industry.
Stave GM; Joines R
Occup Med; 1997; 12(1):1-4. PubMed ID: 9153049
[TBL] [Abstract][Full Text] [Related]
39. The epiphany of data warehousing technologies in the pharmaceutical industry.
Barrett JS; Koprowski SP
Int J Clin Pharmacol Ther; 2002 Mar; 40(3):S3-13. PubMed ID: 11911607
[TBL] [Abstract][Full Text] [Related]
40. Pharmaceutical R&D: the road to positive returns.
David E; Tramontin T; Zemmel R
Nat Rev Drug Discov; 2009 Aug; 8(8):609-10. PubMed ID: 19644471
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
